About Careers Internship MedBlog Contact us

Patent Row No Hurdle for Gilead Pharma's India Plans

by Vishnuprasad on January 28, 2015 at 7:16 PM
Patent Row No Hurdle for Gilead Pharma's India Plans

US drug maker Gilead Pharma says that the recent decision by the patent office, which rejected patent for one of its molecules, does not impact its India plans.

Gilead has announced that it is expanding the voluntary licence agreement with eight Indian companies to include its experimental drug that could cure all the six types of hepatitis C.


The American biotechnology company also makes the new hepatitis C drug Sofosbuvir. Last year, Gilead signed a licensing agreement with Strides, Mylan, Cipla, Dr Reddys, Ranbaxy, Zydus Cadila for Sovaldi.

The drug, priced at $84,000 in US for 12-week treatment, will be sold at $900 in India. It is expected to launch the drug in coming months in India, says the company.

Gregg Alton executive vice-president to ET said that, "We believe that Gilead and Indian companies can make a difference to the world through such partnerships."

Alton also said that the decision by the patent office is only for one of the ancillary molecules and the company does not see this decision as an indication of India's policy on intellectual property.

Source: Medindia
Font : A-A+



Latest Drug News

Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
ADHD Medication Errors Surge by Nearly 300%
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
Unknown Medication Side Effects Reported by 52% of Indian Families
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Patent Row No Hurdle for Gilead Pharma's India Plans Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests